TSUCHIYA Ken
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor (Fixed Term) |
|
Article types | Original article |
Language | English |
Peer review | Non peer reviewed |
Title | Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease |
Journal | Formal name:Scientific reports Abbreviation:Sci Rep ISSN code:20452322 |
Volume, Issue, Page | 12(1),pp.18056 |
Author and coauthor | Kataoka Hiroshi, Akagawa Hiroyuki, Yoshida Rie, Iwasa Naomi, Ushio Yusuke, Akihisa Taro, Sato Masayo, Manabe Shun, Makabe Shiho, Kawachi Keiko, Hoshino Junichi, Tsuchiya Ken, Nitta Kosaku, Mochizuki Toshio |
Publication date | 2022/10/27 |
Summary | Presently, only personal or family history of intracranial aneurysm/subarachnoid hemorrhage (IA/SAH) has been established as a risk factor for IA in autosomal dominant polycystic kidney disease (ADPKD). This study aimed to verify the association between kidney function/volume and IAs in patients with ADPKD. This study included 519 patients with ADPKD. At baseline IA screening, the median age and estimated glomerular filtration rate were 44 years and 54.5 mL/min/1.73 m2, respectively. Family IA/SAH history was confirmed in 18.1% of the patients, and 54.3% of the patients had hypertension. The IA point prevalence was 12.5%. During clinical follow up of 3104 patient-years, de novo IA was detected in 29 patients (0.93% patient-years). The IA period prevalence was 18.1% (median age, 60 years). Multivariable logistic regression demonstrated that total kidney volume (TKV) ≥ 1000 mL (odds ratio [OR] = 2.81), height-adjusted TKV ≥ 500 mL (OR = 2.81), Mayo imaging classification Class 1D-1E (OR = 2.52), and chronic kidney disease stages 3-5 (OR = 2.31) were significantly associated with IA formation. IAs in patients with ADPKD may be associated not only with general risk factors for IAs but also with declining kidney function and increased KV. Kidney disease progression may contribute to effective IA screening and treatment planning in patients with ADPKD. |
DOI | 10.1038/s41598-022-22884-9 |
PMID | 36302803 |